Introduction: EGFR exon 20 insertions comprise 4% to 9% of EGFR mutated NSCLC. Despite being an oncogenic driver, they are associated with primary resistance to EGFR tyrosine kinase inhibitors (TKIs). We hypothesized that dual EGFR blockade with afatinib, an irreversible EGFR TKI, and cetuximab, a monoclonal antibody against EGFR, could induce tumor responses.
Introduction
EGFR exon 20 insertion/duplication mutations (further collectively referred to as "exon 20 insertions") comprise 4% to 9% of EGFR mutated NSCLC. [1] [2] [3] They represent a combination of in-frame insertions and duplications of 3 to 21 nucleotide base pairs, predominantly clustered between codons 767 and 774. Similar to the more common "classic" exon 19 deletion and exon 21 L858R EGFR point mutation, EGFR exon 20 insertions result in sustained EGFR signaling and are oncogenic drivers. 4 However, in contrast to the classic EGFR mutations, insertion mutants in exon 20, with the exception of insertion mutation A763_Y764insFQEA, are associated with resistance to EGFR tyrosine kinase inhibitors (TKIs), including first-and second-generation EGFR TKIs and the third-generation EGFR TKI rociletinib. [5] [6] [7] Although two other third-generation EGFR TKIs, osimertinib and EGF816, showed preclinical antitumor activity in EGFR exon 20 insertion models, it is uncertain whether these results will translate into clinical benefit. 8, 9 A different strategy could be to intensify EGFR blockade by concurrent TKI and monoclonal antibody (mAb) treatment. A study with the second-generation EGFR TKI afatinib and the EGFR mAb cetuximab in patients with advanced EGFR mutation positive NSCLC and acquired resistance to first-generation EGFR TKIs showed that combination treatment is able to *Corresponding author.
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overcome EGFR TKI resistance in patients with classic EGFR mutations, irrespective of T790M status. 10 A study with afatinib and the EGFR mAb nimotuzumab showed comparable results. 11 These studies suggest that dual EGFR blockade with the irreversible EGFR TKI afatinib and an mAb is able to induce tumor responses in patients with a tumor that is driven by EGFR, but resistant to first-and second-generation EGFR TKIs. Based on these results showing that EGFR exon 20 insertion is an oncogenic driver and EGFR TKI resistance can be overcome by dual EGFR inhibition, we treated four patients with EGFR exon 20 insertion-positive NSCLC with afatinib and cetuximab.
Material and Methods
Four patients with stage IV NSCLC harboring an EGFR exon 20 insertion were treated with afatinib and cetuximab in two institutions (VU University Medical Center and The Netherlands Cancer Institute) in the Netherlands. Data were obtained retrospectively by medical record review. EGFR mutation status was assessed by next-generation sequencing (NGS) or high resolution melting followed by Sanger sequencing. EGFR amplification status was determined using chromogenic in situ hybridization (ISH). Mutation and copy number variation analysis by NGS for KRAS, erb-b2 receptor tyrosine kinase 2 (HER2), EGFR, BRAF, MNNG HOS Transforming gene (MET) and fusion analysis by immunohistochemistry or ISH for ALK receptor tyrosine kinase (ALK), ROS1 and ret protooncogene (RET) were performed on pre-treatment biopsy samples and, if available, on post-progression biopsy samples as well.
The first three patients were treated with afatinib (40 mg once daily) and cetuximab (500 mg/m 2 intravenously every 2 weeks) until disease progression or unacceptable toxicity. The fourth patient was treated with afatinib 40 mg once daily and cetuximab 250 mg/m 2 intravenously every 2 weeks. Premedication consisted of metoclopramide 10 mg orally, clemastin 2 mg intravenously, and dexamethasone 8 mg intravenously. Supportive medication consisted of minocycline 100 mg once daily, skin cream and loperamide 2 mg as needed. Follow-up was performed biweekly with physical examination and blood analysis. Radiological follow-up was performed every 6 weeks with computed tomographic scans of the thorax and upper abdomen. Response was assessed according to Response Criteria in Solid Tumors (RECIST) 1.1.
12 Progression-free survival (PFS) was defined as the interval between initiation of afatinib plus cetuximab and the date of radiological progression.
Results
All patients had stage IV adenocarcinoma of the lung harboring an exon 20 insertion. Patient and mutation characteristics are depicted in Table 1 . Additional molecular analysis, including mutations and fusions, did not detect any other common oncogenic drivers. EGFR copy number gain was only present in the tumor biopsy of the first patient.
All patients received prior platinum doublet chemotherapy and two patients were treated with an EGFR TKI as well: patient 3 with a first-generation EGFR TKI and patient 4 with a third-generation EGFR TKI, both without a radiological response. Of the four patients treated with afatinib plus cetuximab, three experienced an objective partial response (PR) according to the RECIST 1.1 (Fig. 1) . The median PFS was 5.4 months (95% confidence interval: 0.0 -14.2 months; range 2.7 months -17.6 months). Patient 1 showed a PFS of 17.6 months. After 10.5 months of treatment, this patient requested temporary interruption of treatment because of a planned holiday. After 8 weeks, a new computed tomographic scan showed clear progression. Upon reintroduction of afatinib and cetuximab, the tumor responded again for 6.5 months.
Toxicity was acceptable and in line with the known toxicity profile of afatinib-cetuximab combination therapy. Patient 1 experienced grade II skin toxicity and paronychia. After 15 months of treatment, this led to a dose reduction of afatinib to 30 mg once daily. The afatinib dose was reduced to 30 mg as well in patient 2 due to grade III skin toxicity and grade II diarrhea. This was followed by a dose reduction of cetuximab (250 mg/m 2 ) because of ongoing toxicity. Patient 3 had grade I skin toxicity and grade I diarrhea. Due to progression, treatment was discontinued after 2.7 months. Patient 4 was treated with a lower dose of cetuximab (250 mg/m 2 ) in combination with afatinib 40 mg once daily because of WHO performance status of 3. She experienced grade I skin toxicity and paronychia and grade II diarrhea that were managed with supportive medication. She experienced a PR and her WHO performance status improved to 1.
Post-progression biopsy samples were available for both patients who experienced a PR, whereas patient 4 is still on treatment with an ongoing response. Both biopsy samples were analyzed for mutations with NGS, as well as copy number changes for EGFR, MET, and HER2 with ISH. Both samples were positive for the known exon 20 insertion and negative for T790M point mutation. In the paired biopsy samples of patient 1, polysomy of the MET proto-oncogene was present with 4 to 5 copies/nucleus compared to 3 copies before treatment, suggestive of bypass track resistance.
Discussion
EGFR exon 20 insertions are associated with primary resistance to EGFR TKI treatment. These mutations activate EGFR without reducing the affinity for adenosine triphosphate or increasing the affinity for EGFR TKIs like sensitive EGFR mutants do, possibly by rearrangement of the C-helix. 4 At present, treatment options for these patients are limited. The treatment of choice in the first-line setting is platinum-based chemotherapy and responses are consistent with the results seen with treatment of advanced lung adenocarcinoma in general. 7 In this series, we have treated four patients with previously described EGFR exon 20 insertion variants, which are thought to confer resistance to EGFR TKIs. 1, 3, 4 Two of four patients were treated with an EGFR TKI, including one patient with the thirdgeneration EGFR TKI osimertinib, without a radiological response. All patients received afatinib plus cetuximab, a combination of an irreversible ErbB family blocker that selectively blocks signaling from all ErbB family receptors and a chimeric, human-murine anti-EGFR mAb that binds with high affinity to the extracellular domain of EGFR. Three of four patients had a PR and the median PFS was 5.4 months. In all cases, toxicity was manageable.
The clinical activity of afatinib plus cetuximab supports the hypothesis that dual EGFR inhibition can be effective in patients with EGFR exon 20 insertionpositive NSCLC. Because these tumors are dependent on EGFR signaling, we hypothesized that intensification of EGFR blockade could induce tumor responses, as was also shown for patients with EGFR TKI sensitive EGFR mutations and secondary resistance to EGFR TKIs. 10 Wheler et al. 13 treated 20 NSCLC patients with erlotinib and cetuximab. One patient with an EGFR exon 20 insertion was included in this trial and this patient experienced a PR. Vanderbilt et al. 14 reported two patients with EGFR exon 20 insertions who showed PRs on different cetuximab-containing regimens (one patient was treated with afatinib and cetuximab and one with carboplatin and gemcitabine in combination with cetuximab).
Analysis of post-progression samples revealed an increase in the MET gene copy number in one patient, suggestive of MET bypass track resistance, a known resistance mechanism to EGFR TKIs. 15, 16 EGFR gene amplification has been postulated as a possible biomarker for EGFR mAb treatment benefit. A recent study observed a trend for greater necitumumab benefit in EGFR fluorescent in situ hybridization (FISH)-positive squamous NSCLC patients. 17 However, in our case series, pre-treatment EGFR gene copy numbers were low for two of three responding patients.
In conclusion, this case series suggests that afatinib and cetuximab combination treatment is able to overcome primary EGFR TKI resistance in patients with EGFR exon 20 insertion-positive NSCLC. Treatment with the combination resulted in a PR in three of four patients and a median PFS of 5.4 months. These results will be validated in a dedicated clinical trial.
